Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis

被引：0
|
作者：
Juanzhi Fang
Stephanie Korrer
Jonathan C. Johnson
Mark A. Cheadle
Roshani Shah
Matias L. Ferraris
Cristina Lopez-Lopez
机构：
[1] Novartis Pharmaceuticals Corporation,
[2] Optum,undefined
[3] Novartis Pharma AG,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Acute; Comorbidity; Erenumab; Migraine; Observational; Preventive; Real world; Retrospective;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2921 / 2934
页数：13
相关论文
共 50 条
  • [21] Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
    Antonio Russo
    Marcello Silvestro
    Fabrizio Scotto di Clemente
    Francesca Trojsi
    Alvino Bisecco
    Simona Bonavita
    Alessandro Tessitore
    Gioacchino Tedeschi
    The Journal of Headache and Pain, 2020, 21
  • [22] Erenumab Decreases Headache-Related Sick Leave Days and Health Care Visits: A Retrospective Real-World Study in Working Patients with Migraine
    Henri Autio
    Timo Purmonen
    Samu Kurki
    Emina Mocevic
    Minna A. Korolainen
    Samuli Tuominen
    Mariann I. Lassenius
    Markku Nissilä
    Neurology and Therapy, 2022, 11 : 223 - 235
  • [23] Erenumab Decreases Headache-Related Sick Leave Days and Health Care Visits: A Retrospective Real-World Study in Working Patients with Migraine
    Autio, Henri
    Purmonen, Timo
    Kurki, Samu
    Mocevic, Emina
    Korolainen, Minna A.
    Tuominen, Samuli
    Lassenius, Mariann I.
    Nissila, Markku
    NEUROLOGY AND THERAPY, 2022, 11 (01) : 223 - 235
  • [24] Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
    Andreou, Anna P.
    Fuccaro, Matteo
    Hill, Bethany
    Murphy, Madeleine
    Caponnetto, Valeria
    Kilner, Rachael
    Lambru, Giorgio
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01)
  • [25] Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis
    Fernandez-Bravo-Rodrigo, Jaime
    Cavero-Redondo, Ivan
    Luceron-Lucas-Torres, Maribel
    Martinez-Garcia, Irene
    Flor-Garcia, Amparo
    Barreda-Hernandez, Dolores
    Pascual-Morena, Carlos
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 976
  • [26] Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
    Anna P. Andreou
    Matteo Fuccaro
    Bethany Hill
    Madeleine Murphy
    Valeria Caponnetto
    Rachael Kilner
    Giorgio Lambru
    The Journal of Headache and Pain, 2022, 23
  • [27] Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany
    Hong, Ja Bin
    Lange, Kristin Sophie
    Fitzek, Mira
    Overeem, Lucas Hendrik
    Triller, Paul
    Siebert, Anke
    Reuter, Uwe
    Raffaelli, Bianca
    JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01)
  • [28] Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany
    Ja Bin Hong
    Kristin Sophie Lange
    Mira Fitzek
    Lucas Hendrik Overeem
    Paul Triller
    Anke Siebert
    Uwe Reuter
    Bianca Raffaelli
    The Journal of Headache and Pain, 24
  • [29] Exploring Erenumab's Efficacy and Safety for Migraine Prevention in Real-World Settings: A Systematic Review
    Nisar, Mah Rukh
    Kotha, Rudrani
    Saad-Omer, Sabaa I.
    Singh, Shivani
    Olayinka, Oluwatoba T.
    Orelus, Jaslin
    Yu, Ann Kashmer
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [30] Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
    Tsubasa Takizawa
    Seiya Ohtani
    Narumi Watanabe
    Naoki Miyazaki
    Kei Ishizuchi
    Koji Sekiguchi
    Chisato Iba
    Mamoru Shibata
    Ryo Takemura
    Satoko Hori
    Jin Nakahara
    BMC Neurology, 22
12345